EUCTR2015-003820-30-SK进行中（未招募）1 期
A MULTICENTER, SINGLE ARM, OPEN LABEL, EXPLORATORY PROSPECTIVE PHASE II STUDY TO EXPLORE THE EFFICACY, SAFETY AND TOLERABILITY OF DEUTERIUM DEPLETED WATER IN PREVIOUSLY UNTREATED PATIENTS WITH ASYMPTOMATIC CHRONIC LYMPHOCYTIC LEUKEMIA BUT WHO ARE AT HIGH RISK OF PROGRESSION.
HYD Pharma Zrt.0 个研究点目标入组 25 人开始时间: 2015年11月30日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written and signed informed consent according to local guidelines.
- •2. Male and female subjects >= 18 years of age.
- •3. Body weight <= 90 kg.
- •4. Histopathologically confirmed diagnosis of asymptomatic early stage CLL (Binet A) who are at high risk of progression (= 2 risk factors).
- •5. No previous treatment for asymptomatic early stage CLL (Binet A).
- •6. ECOG performance status <= 2.
- •7. Life expectancy >= 6 months.
- •8. Adequate liver function as defined as:
- •a. Serum (total) bilirubin <= 2 x the upper limit of normal (ULN)
- •b. Aspartate aminotransferase (ASAT) or serum glutamic oxaloacetic transaminase (SGOT) <= 2,5 x ULN
- •c. Alanine aminotransferase (ALAT) or serum glutamic-pyruvix transaminase (SGPT) <= 2,5 x ULN
- •d. Alkaline phosphatase (AP) <= 2,5 x ULN
- •9. Adequate renal function as defined as:
- •a. Serum creatinine <= 1.5 ULN
- •b. Aspartate aminotransferase (ASAT) or serum glutamic oxaloacetic transaminase (SGOT) <= 2,5 x ULN
- •c. Alanine aminotransferase (ALAT) or serum glutamic-pyruvix transaminase (SGPT) <= 2,5 x ULN
- •d. Alkaline phosphatase (AP) <= 2,5 x ULN
- •9. Adequate renal function as defined as:
- •a. Serum creatinine <= 1.5 ULN
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 21
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 4
排除标准
- •1. Subjects currently consuming or who have already consumed DDW.
- •2. History of other malignancy, other than non-basal-cell carcinoma of the skin or in situ carcinoma of the cervix unless the tumor was treated with curative intent at least 2 years previously which could affect the diagnosis or assessment of CLL.
- •3. Subjects with any of the following concurrent conditions:
- •Evidence or history of significant cardiovascular, endocrine or metabolic disease
- •Unstable angina pectoris, uncontrolled arrhythmia and cardiac insufficiency (NYHA Class III-IV).
- •Serious intercurrent medical conditions that may interfere with the planned treatment (including human immunodeficiency virus (HIV)-positive, serious active infection, central nervous system (CNS) disease, psychiatric illness.) Patient with active infections requiring systemic antibiotics should be excluded from the study until resolution of infection.
- •Clinically significant hepatic or renal disease.
- •Evidence or history of alcohol-, drug and/or medical abuse.
- •Other severe, concurrent disease(s) or mental disorder.
- •4. Subjects who have been hospitalized, had surgery with full recovery or have received emergency treatment in the 4 weeks prior to the start of the study.
- •5. Subjects currently receiving other investigational medication or who have received investigational medication in the month prior to the screening of the study.
- •6. Subjects who are unlikely to be compliant or attend scheduled clinic visits and follow up as required or who are unlikely to be compliant with the recommendations of the protocol, in particular subjects who undertake regular sporting or above average physical activity.
- •7. Employees of the Sponsor or the contract research organization (CRO) responsible for the execution of the study.
- •8. For female patients of childbearing potential (defined as < 2 years after last menstruation and not surgically sterile) and male patients who are not surgically sterile or with female partners of childbearing potential: absence of effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal gel).
- •9. Pregnancy or lactation (female patients). Serum pregnancy test to be performed within 7 days prior to study treatment start.
- •10. Subjects who keep a strict vegetarian diet.
研究者
相似试验
进行中（未招募）
1 期
A Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary FibrosisEUCTR2015-003280-11-ESRoche Farma S.A., que representa en España a F. Hoffmann-La Roche Ltd80
已完成
4 期
AN EXPLORATORY MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF THE SAFETY AND TOLERABILITY OF PIRFENIDONE (ESBRIET®) IN COMBINATION WITH NINTEDANIB (OFEV®) IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS10035597Idiopathic pulmonary fibrosispulmonary fibrosisNL-OMON43469Roche Nederland B.V.8
进行中（未招募）
1 期
A Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)MedDRA version: 19.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-003280-11-NLF. Hoffmann-La Roche Ltd80
进行中（未招募）
1 期
A Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary FibrosisEUCTR2015-003280-11-ITF. HOFFMANN - LA ROCHE LTD.89
进行中（未招募）
1 期
A Study of the Safety and Tolerability of Pirfenidone (Esbriet) in Combination with Nintedanib (Ofev) in Patients with Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)MedDRA version: 19.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2015-003280-11-DEF. Hoffmann-La Roche Ltd80